Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib in Limited-Stage Small Cell Lung Cancer
NCT07473128Phase 3Recruiting
- Sponsor
- Pharmacosmos
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trilaciclib in small cell lung cancer (SCLC), sponsored by Pharmacosmos. Started Sep 2026; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07473128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473128.